February 2025 US Penny Stocks With Promising Prospects
Name
Share Price
Market Cap
Financial Health Rating
QuantaSing Group (NasdaqGM:QSG)
$3.08
$127.27M
★★★★★★
BAB (OTCPK:BABB)
$0.88
$6.39M
★★★★★★
Imperial Petroleum (NasdaqCM:IMPP)
$2.79
$84.63M
★★★★★★
ZTEST Electronics (OTCPK:ZTST.F)
$0.249
$9.16M
★★★★★★
Permianville Royalty Trust (NYSE:PVL)
$1.41
$46.53M
★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)
$4.50
$67.38M
★★★★★★
Smith Micro Software (NasdaqCM:SMSI)
$1.39
$24.65M
★★★★★☆
PHX Minerals (NYSE:PHX)
$4.13
$154.8M
★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)
$0.8718
$78.41M
★★★★★☆
Safe Bulkers (NYSE:SB)
$3.59
$383.33M
★★★★☆☆
Click here to see the full list of 702 stocks from our US Penny Stocks screener.
Let's dive into some prime choices out of the screener.
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Genenta Science S.p.A. is a clinical-stage biotechnology company based in Italy that focuses on developing hematopoietic stem cell gene therapies for treating solid tumors, with a market cap of $79.90 million.
Operations: Currently, there are no reported revenue segments for Genenta Science.
Market Cap: $79.9M
Genenta Science, a clinical-stage biotech firm, is pre-revenue with no significant revenue streams and a market cap of US$79.90 million. Despite being unprofitable with increasing losses over the past five years, Genenta maintains financial stability with its short-term assets exceeding liabilities and no debt on its books. The company has a cash runway of 2.9 years if current cash flow trends persist. Recent strategic developments include an enhanced partnership with AGC Biologics for exclusive manufacturing capabilities in Milan, potentially boosting production efficiency as it advances trials for metastatic Renal Cell Cancer and Glioblastoma Multiforme therapies.
Click to explore a detailed breakdown of our findings in Genenta Science's financial health report.
Explore Genenta Science's analyst forecasts in our growth report.
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Black Diamond Therapeutics, Inc. is a clinical-stage oncology medicine company specializing in the discovery and development of MasterKey therapies for genetically defined tumors, with a market cap of $134.11 million.
Operations: Black Diamond Therapeutics, Inc. does not report any revenue segments as it is currently in the clinical stage of developing oncology medicines.
Market Cap: $134.11M
Black Diamond Therapeutics, with a market cap of US$134.11 million, is a pre-revenue clinical-stage oncology company focused on MasterKey therapies for genetically defined tumors. Despite being unprofitable and experiencing increasing losses at 9.9% annually over the past five years, it remains debt-free and financially stable with short-term assets of US$115.5 million covering its liabilities. The company has enough cash to sustain operations for over a year if current cash flow trends continue or 1.5 years if cash outflow decreases by historical rates. Shareholder dilution has been minimal despite high share price volatility recently observed in the market.
Click here and access our complete financial health analysis report to understand the dynamics of Black Diamond Therapeutics.
Examine Black Diamond Therapeutics' earnings growth report to understand how analysts expect it to perform.
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: BRC Inc. operates in the United States, focusing on purchasing, roasting, and selling coffee along with coffee accessories and branded apparel, with a market cap of approximately $557.39 million.
Operations: The company generates revenue primarily from its Consumer Products Business, which accounts for $405.26 million.
Market Cap: $557.39M
BRC Inc., with a market cap of US$557.39 million, is unprofitable but maintains a stable position in the coffee industry, generating significant revenue from its Consumer Products Business. The company has not experienced meaningful shareholder dilution over the past year and benefits from a cash runway exceeding three years, despite shrinking free cash flow. While BRC's short-term assets (US$103 million) cover both short-term and long-term liabilities, its high net debt to equity ratio (107.5%) is concerning. Recent guidance reaffirms 2024 net revenue expectations between US$390 million and US$395 million, highlighting potential growth amidst financial challenges.
Click here to discover the nuances of BRC with our detailed analytical financial health report.
Evaluate BRC's prospects by accessing our earnings growth report.
Click this link to deep-dive into the 702 companies within our US Penny Stocks screener.
Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Jump on the AI train with fast growing tech companies forging a new era of innovation.
Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqCM:GNTA NasdaqGS:BDTX and NYSE:BRCC.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Wall Street thinks the party for Palantir can continue even after a wild rally in 2025 — but there's one key risk
Palantir is the top-performing stock in the S&P 500 this year, and Wall Street is upbeat about what's ahead. Palantir has been on a tear, climbing 113% since the start of the year. A lofty valuation is the main risk analysts are eyeing heading into second-quarter earnings. Wall Street thinks the Palantir party can keep going. The stock is already up by about 113% this year as it heads into its second-quarter earnings report after the bell on Monday, but analysts see reasons to believe the gains can pile up further. The Alex Karp-led software giant is benefiting from a slew of government contracts, roaring AI demand, and a cultlike following among retail investors in 2025. Shares of the company have soared from around $75 a share at the start of 2025 to above $160 on Monday. That ascent has made Palantir the best-performing stock in the S&P 500 this year. Analysts are bullish about Palantir's second-quarter earnings. They estimate the tech giant will report $939.3 million in revenue for the three-month period, up around 38% year over year. Here are some of the reasons they see the growth story continuing — and one key risk. 1. The AI trade is still running hot Palantir will likely keep up growth in its commercial segment, thanks to the ongoing hype surrounding AI. Accelerating AI adoption is creating a greater need to integrate data, which is good news for the stock, analysts at Mizuho wrote in a note. The bank said it conducted checks on Palantir's enterprise inbound activity, which gave it confidence that the company would be able to beat its commercial growth guidance in 2025. Palantir expects the US commercial side of its business to grow 68% for the year. "PLTR's recent execution and momentum is stunning, including material upward revisions across its commercial and government segments that we very much underestimated," Mizuho analysts wrote. Analysts at UBS said they also conducted checks on Palantir's enterprise businesses, and lifted their estimates for the company's revenue growth from 31% to 38% for the year. "We see potential tailwinds from the increasing adoption of AI across enterprise," Citi analysts wrote, adding that its checks and its conversation with Palantir's chief finance officer were also positive. Government contracts A large part of Palantir's growth story has been fueled by its contracts with the federal government. In April, the software company secured a $30 million deal with the US Immigration and Customs Enforcement for software to monitor visas and track deportations. In May, the firm teamed up with Fannie Mae, and said it would provide AI tools to support the government-sponsored mortgage financier's Crime Detection Unit. It also secured a $795 million contract with the Department of Defense's AI arm, and last week, locked a deal to help streamline the US Army for up to $10 billion for the next decade. The deal consolidates 75 existing contracts into a single agreement. "We believe this deal represents an additional tailwind for PLTR with AI initiatives across the US government accelerating with AI a strategic focus on the federal front and Palantir in the sweet spot to benefit from a tidal wave of federal spending on AI," analysts at Wedbush Securities wrote last week, calling Palantir one of the top tech stocks to own in 2025. "We remain positive on the public sector pipeline, which appears durable given ongoing geopolitical instability. Net, we believe PLTR will likely be able to continue growing its Government revenue >40% Y/Y over at least the near-term," Mizuho said. "We continue to view Palantir as well positioned to continue to deliver best-in-class growth given the secular trend towards enterprise AI adoption; the continued push for efficiency and technology adoption in the US government; and adoption of Operation Warp Speed among new defense entrants, traditional defense companies, and the broader manufacturing industry," analyst at Goldman Sachs wrote in a note following Palantir's first-quarter earnings report in May. High bar But there's one risk Wall Street is eyeing: the valuation is at eye-watering levels. As of Monday afternoon, the trailing 12-month price-to-earnings ratio was above 690x. Despite a bullish short-term outlook, Goldman Sachs, UBS, and Mizuho are among those on Wall Street who rated Palantir as "neutral" headed into its second-quarter earnings. Analysts at Citi, meanwhile, rated the stock as "Neutral/High Risk." "We maintain our Neutral/High Risk rating on the stock on valuation concerns and our view that second derivative/revision trends could moderate limiting upside," Citi added in a note. "That said, we are equally stunned by the multiple that PLTR has attained, which places its valuation dramatically above anything else in software," Mizuho analysts said, adding they would "continue to worry" that the stock could see a reversion sometime in the next several quarters. "We continue to be very impressed by the fundamental story (we have been since our launch) but valuation remains our key hurdle, we remain Neutral rated," UBS said. Read the original article on Business Insider Sign in to access your portfolio
Wall Street Journal
17 minutes ago
- Wall Street Journal
China's Services Sector Activity Accelerates
A private gauge of China's services sector showed activity expanded at the fastest pace in more than a year in July, as demand improved during the summer travel rush. The S&P Global China general services purchasing managers index rose to 52.6 last month from June's 50.6, according to data released Tuesday by S&P Global. A reading above 50 suggests an expansion in activity, while a reading below suggests contraction.
Yahoo
35 minutes ago
- Yahoo
Trex's (NYSE:TREX) Q2 Sales Top Estimates
Composite decking and railing products manufacturer Trex Company (NYSE:TREX) beat Wall Street's revenue expectations in Q2 CY2025, with sales up 3% year on year to $387.8 million. On the other hand, next quarter's revenue guidance of $300 million was less impressive, coming in 1% below analysts' estimates. Its non-GAAP profit of $0.73 per share was 2.8% above analysts' consensus estimates. Is now the time to buy Trex? Find out in our full research report. Trex (TREX) Q2 CY2025 Highlights: Revenue: $387.8 million vs analyst estimates of $377.1 million (3% year-on-year growth, 2.8% beat) Adjusted EPS: $0.73 vs analyst estimates of $0.71 (2.8% beat) Adjusted EBITDA: $122 million vs analyst estimates of $117.9 million (31.5% margin, 3.5% beat) Revenue Guidance for Q3 CY2025 is $300 million at the midpoint, below analyst estimates of $303.1 million Operating Margin: 26.4%, down from 31.1% in the same quarter last year Free Cash Flow Margin: 52.3%, up from 42% in the same quarter last year Market Capitalization: $6.8 billion 'Our prominent position in both the pro channel and home centers enabled Trex to deliver another quarter of sales performance that exceeded expectations,' said Bryan Fairbanks, President and CEO. Company Overview Addressing the demand for aesthetically-pleasing and unique outdoor living spaces, Trex Company (NYSE:TREX) makes wood-alternative decking, railing, and patio furniture. Revenue Growth Examining a company's long-term performance can provide clues about its quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Thankfully, Trex's 7.7% annualized revenue growth over the last five years was decent. Its growth was slightly above the average industrials company and shows its offerings resonate with customers. Long-term growth is the most important, but within industrials, a half-decade historical view may miss new industry trends or demand cycles. Trex's annualized revenue growth of 7.6% over the last two years aligns with its five-year trend, suggesting its demand was stable. This quarter, Trex reported modest year-on-year revenue growth of 3% but beat Wall Street's estimates by 2.8%. Company management is currently guiding for a 28.4% year-on-year increase in sales next quarter. Looking further ahead, sell-side analysts expect revenue to grow 13% over the next 12 months, an improvement versus the last two years. This projection is noteworthy and suggests its newer products and services will catalyze better top-line performance. Software is eating the world and there is virtually no industry left that has been untouched by it. That drives increasing demand for tools helping software developers do their jobs, whether it be monitoring critical cloud infrastructure, integrating audio and video functionality, or ensuring smooth content streaming. Click here to access a free report on our 3 favorite stocks to play this generational megatrend. Operating Margin Operating margin is one of the best measures of profitability because it tells us how much money a company takes home after procuring and manufacturing its products, marketing and selling those products, and most importantly, keeping them relevant through research and development. Trex has been a well-oiled machine over the last five years. It demonstrated elite profitability for an industrials business, boasting an average operating margin of 24.5%. This result isn't surprising as its high gross margin gives it a favorable starting point. Looking at the trend in its profitability, Trex's operating margin decreased by 3.3 percentage points over the last five years. This raises questions about the company's expense base because its revenue growth should have given it leverage on its fixed costs, resulting in better economies of scale and profitability. In Q2, Trex generated an operating margin profit margin of 26.4%, down 4.6 percentage points year on year. Since Trex's operating margin decreased more than its gross margin, we can assume it was less efficient because expenses such as marketing, R&D, and administrative overhead increased. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Trex's EPS grew at an unimpressive 4.5% compounded annual growth rate over the last five years, lower than its 7.7% annualized revenue growth. This tells us the company became less profitable on a per-share basis as it expanded due to non-fundamental factors such as interest expenses and taxes. We can take a deeper look into Trex's earnings to better understand the drivers of its performance. As we mentioned earlier, Trex's operating margin declined by 3.3 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its lower earnings; interest expenses and taxes can also affect EPS but don't tell us as much about a company's fundamentals. Like with revenue, we analyze EPS over a shorter period to see if we are missing a change in the business. For Trex, its two-year annual EPS growth of 10.7% was higher than its five-year trend. This acceleration made it one of the faster-growing industrials companies in recent history. In Q2, Trex reported adjusted EPS at $0.73, down from $0.80 in the same quarter last year. Despite falling year on year, this print beat analysts' estimates by 2.8%. Over the next 12 months, Wall Street expects Trex's full-year EPS of $1.79 to grow 34.1%. Key Takeaways from Trex's Q2 Results We enjoyed seeing Trex beat analysts' revenue expectations this quarter. We were also happy its EBITDA outperformed Wall Street's estimates. On the other hand, its revenue guidance for next quarter slightly missed. Overall, this print was mixed. The stock remained flat at $64.50 immediately following the results. Sure, Trex had a solid quarter, but if we look at the bigger picture, is this stock a buy? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
